Name
Viridian Therapeutics, Inc.
Company Description
Viridian Therapeutics is developing potential best-in-class medicines for people living with autoimmune and rare diseases, including multiple clinical candidates for the treatment of thyroid eye disease (TED). Viridian aims to advance veligrotug (VRDN-001) as a differentiated intravenous therapy and VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED.
Product Categories (5)
Pharmaceutical
Address
221 Crescent St.
Suite 103A
Waltham, MA 02453
United States
Suite 103A
Waltham, MA 02453
United States